Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Mito ou verdade: O frequente uso de chuteira pode provocar a micose de unha?


News provided by

Galderma

Nov 28, 2022, 09:35 ET

Share this article

Share toX

Share this article

Share toX

A resposta é sim! Sapatos fechados podem propiciar o aparecimento da micose nas unhas e frieiras. Isso porque os pés ficam abafados por um longo período deixando o local úmido e quente, uma condição favorável para o aparecimento de fungos1

SÃO PAULO, 28 de novembro de 2022 /PRNewswire/ -- Em tempos de campeonato mundial, não se fala em outra coisa: futebol. Mais do que ser tema em grande parte das conversas, uma época como essa faz com que o esporte se torne ainda mais popular, despertando o desejo pela prática e tudo o que a envolve. O uso de chuteiras, entretanto, requer cuidados com a saúde dos pés, pois é um ambiente favorável para a proliferação de fungos e infecções causadas por eles, como a micose de unha.

Continue Reading

Pra quem se pergunta se é mito ou verdade que o uso contínuo de chuteira pode provocar a micose de unha, fica aqui a resposta. É verdade. Não só as chuteiras, mas o uso contínuo de sapatos fechados de modo geral realmente pode motivar o aparecimento de fungos nos pés e nas unhas. No caso da prática esportiva, soma-se a isso ao suor causado na região pelo ritmo intenso e prolongado das atividades.

A micose de unha é causada por fungos que se alimentam da queratina, proteína presente nas unhas, e é mais comum nas unhas dos pés. Isso se deve ao fato de ser uma região pouco arejada e que geralmente está abafada por um calçado fechado, como as chuteiras.

Além disso, as unhas dos pés crescem mais lentamente do que as das mãos, o que favorece a penetração e disseminação dos fungos¹.

No entanto, independentemente do gatilho para o acometimento dos fungos, a micose de unhas deve ser tratada. Felizmente, isso pode ser feito com o uso de esmaltes antifúngicos e é importante que o tratamento comece assim que a doença for diagnosticada. Caso isso não aconteça, a micose pode se agravar, vale também manter a atenção redobrada durante o tratamento em casos de pessoas com diabetes, psoríase, imunossupressão, obesidade, hiperidrose, tabagismo, doenças vasculares e alterações ósseas¹.

Loceryl® Esmalte é um esmalte antifúngico recomendado para tratar a micose de unha.  Ele conta com amorolfina em sua composição, um ingrediente ativo antifúngico que atua na eliminação dos fungos causadores da infecção². Este esmalte terapêutico cobre e penetra na unha para continuar eliminando os fungos durante 7 dias². Além desse efeito de longa duração*, combate diversas classes de fungos causadores da micose de unha². Também é o 1° esmalte terapêutico do mercado com amorolfina que permite o uso de esmaltes cosméticos³**, sem perder a eficácia do produto.

É fundamental consultar um dermatologista para avaliar o caso e indicar a melhor solução.

Loceryl® Esmalte (cloridrato de amorolfina) é indicado para o tratamento de micoses de unha (onicomicoses).  Reg. MS 1.2916.0036. GALDERMA BRASIL LTDA./LOCERYLESM-MB01_20/SAC: 0800 015 5552. LOCERYL® ESMALTE É UM MEDICAMENTO. SEU USO PODE TRAZER RISCOS. PROCURE O MÉDICO E O FARMACÊUTICO. LEIA A BULA. SE PERSISTIREM OS SINTOMAS, O MÉDICO DEVERÁ SER CONSULTADO.

*Uma única aplicação do esmalte fornece proteção por uma semana.

**necessário aguardar 10 minutos para aplicação do esmalte cosmético

¹Sociedade Brasileira de Dermatologia. Onicomicose: transmissão, sintomas e como tratar as unhas. Disponível em: https://www.sbd-sp.org.br/geral/onicomicose-transmissao-sintomas-e-como-tratar-as-unhas/ Acesso em 24 de fev. de 2022.

²Endringer Pinto F, Bagger C, Kunze G, et al. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging. Mycoses. 2020 Aug;63(8):869-875.

³Sigurgeirsson B, Ghannoum MA, Osman-Ponchet H, et al. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised activecontrolled study and in vitro assays. Mycoses. 2016 May;59(5):319-26

Sobre a Galderma

A Galderma é a empresa líder na categoria exclusivamente dedicada à dermatologia, presente em aproximadamente 90 países. Fornecemos um portfólio inovador e baseado na ciência de marcas e serviços premium que abrangem todo o espectro do mercado de dermatologia em rápido crescimento, por meio de Estética Injetável, Dermocosméticos e Dermatologia Terapêutica. Desde nossa fundação em 1981, dedicamos nosso foco e paixão ao maior órgão do corpo humano – a pele – atendendo às necessidades individuais de consumidores e pacientes com resultados superiores em parceria com profissionais de saúde. Estamos avançando a dermatologia para cada história de pele, porque entendemos que a pele em que estamos molda nossas histórias de vida. Para mais informações, visite: https://loceryl.com.br/

Foto - https://mma.prnewswire.com/media/1956528/Loceryl.jpg

FONTE Galderma

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership

Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the establishment of its new U.S. headquarters in Miami, Florida,...

GALDERMA LAUNCHES "SCRATCH RESISTANCE" CAMPAIGN TO VALIDATE THE PHYSICAL AND EMOTIONAL BURDENS OF ATOPIC DERMATITIS

GALDERMA LAUNCHES "SCRATCH RESISTANCE" CAMPAIGN TO VALIDATE THE PHYSICAL AND EMOTIONAL BURDENS OF ATOPIC DERMATITIS

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of "Scratch Resistance," its new broadcast advertisement...

More Releases From This Source

Explore

Cosmetics and Personal Care

Cosmetics and Personal Care

Health Care & Hospitals

Health Care & Hospitals

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

Surveys, Polls and Research

Surveys, Polls and Research

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.